Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-directed monoclonal antibodies in non-small cell lung cancer.

Targeted oncology - 1 Mar 2013

Pirker Robert

Abstract excerpt

Several monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been evaluated in patients with non-small cell lung cancer (NSCLC). Cetuximab, a chimeric monoclonal antibody, has been studied in combination with first-line chemotherapy in phase II and two phase III trials in patients with advanced NSCLC. The phase III FLEX trial demonstrated an increase in survival for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to KRAS gene

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 23300028
DOI: 10.1007/s11523-012-0244-7

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-directed monoclonal antibodies in non-small cell lung cancer.PMID 23300028Read ↗

Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.Semantic proximity Read ↗

Monoclonal antibodies in lung cancer.Semantic proximity Read ↗

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.Semantic proximity Read ↗

EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation.Semantic proximity Read ↗

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation.Semantic proximity Read ↗

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.Semantic proximity Read ↗

Cetuximab, its clinical use and future perspectives.Semantic proximity Read ↗

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.Semantic proximity Read ↗

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapySemantic proximity Read ↗

Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.